Ohad Yogev
Vice President, Discovery ScionxBio
Seminars
Thursday 29th October 2026
Single-Dose xRNA Enables Weeks of Sustained Incretin Therapy
1:30 pm
- Engineering xRNA to give weeks of GLP-1 pharmacology from one injection
- Optimising RNA chemistry to increase expression potency and durability beyond conventional mRNA
- Flattening peak-and-trough exposure to improve tolerability and adherence
Wednesday 28th October 2026
Panel & Audience Discussion: Evaluating Oral, Injectable & DNA Delivery Methods to Align Modality Selection with Clinical Performance & Commercial Scale
4:15 pm
- Comparing modality trade-offs in potency, safety and half-life between oral small molecules and injectable peptide therapeutics to guide smarter development decisions
- Exploring how advances in oral delivery and next-generation formats to expand treatment options beyond injectables
- Discussing the manufacturing strengths and pitfalls of oral, DNA and injectable peptide therapies to align delivery mechanisms with commercial viability and faster routes to market
